Lymphatic mapping, a recent technique first developed for the management of melanoma, is based on the concept that information about the status of the entire lymphatic drainage from a tumor site could ...

After neoadjuvant breast cancer treatment, axillary radiotherapy may offer an effective alternative to axillary lymph node dissection.

Learn Look Locate launches a groundbreaking guide on lymph node surgery in breast cancer, offering clear, expert-led ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Sentinel lymph nodes (SLNs) serve as the first checkpoint in breast cancer metastasis and play a crucial role in halting cancer progression. However, in advanced cancers with metastatic potential, ...

SAN ANTONIO – Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...

Sentinel lymph node biopsy has replaced traditional axillary dissection, minimizing lymphedema risk in breast cancer surgery. The procedure targets the first draining lymph nodes, reducing unnecessary ...

We read with interest the Article by Giacomo Montagna and colleagues1 evaluating oncological outcomes in patients with residual nodal micrometastatic disease (ypN1mi) following neoadjuvant systemic ...

What was once 25 treatments over five weeks can now often be delivered in 16 treatments, or even as few as five fractions.

or on the link below. In 2025, ASCO published a guideline update on the use of sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer (stages I and II) treated with up-front ...

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...